

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
Sep 17, 2024
Biotech IPOs are on the rise, with three companies making successful NASDAQ debuts. The discussion dives into the parallels between GLP-1 treatments for obesity and the successful PD-1 cancer drugs. There's also a thrilling exploration of how AI is transforming biopharma, from data quality to innovative strategies. Recent conferences shed light on future trends in obesity research and the evolving investment landscape for tech and biotech firms. Tune in for insights that blend market dynamics and groundbreaking scientific developments!
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Intro
00:00 • 2min
Revitalizing Biotech IPOs
01:31 • 8min
Upcoming Conferences and Insights on Obesity Research
09:07 • 3min
Navigating the GLP-1 Treatment Landscape
11:50 • 17min
Navigating the Tech-Biotech Investment Landscape
28:36 • 2min
Engaging Listeners and Future Podcast Plans
30:20 • 3min